IntegraGen Launches ARISk™ Test, a Genetic Screening Tool for Autism in High-Risk Children
The ARISk™ Test Screens Children in Multiplex Families As Early As Six Months by Looking at 65 Genetic Markers Associated With Autism, Paving Way for Early Intervention and Best Outcomes
Cambridge, MA (April 4, 2012)-- IntegraGen, Inc., a biotechnology company dedicated to molecular biomarker discovery, today announced the launch of the ARISk™ Risk Assessment Test, a gender specific, genetic screening test that looks at 65 genetic markers associated with Autism Spectrum Disorder (ASD). The test is designed to assess the risk of autism in children from multiplex families—siblings of children with ASD who are 6 to 30 months of age. According to the Centers for Disease Control (CDC), the average age of diagnosis for ASD is 4.0 years, despite conclusive evidence that early intervention can significantly improve IQ scores, language and social skills, and ensure best possible outcomes.
Results from New Test Designed to Aid in the Earlier Identification of Children at Higher Risk of Autism
Cambridge, MA, Evry, France, 19 September 2011 –
IntegraGen, a biotechnology company dedicated to gene discovery and the development of molecular diagnostic products and services, announced today the results of a study which reports the ability to better predict the risk of autism in children who have an older sibling diagnosed with an autism spectrum disorder (ASD). The study, presented during the Society for Developmental and Behavioral Pediatrics meeting in San Antonio, Texas, is based on a test which identifies genetic variants which the researchers showed to be associated with autism. Over 1,200 families and nearly 2,000 children were included in the study.